Ironwood Pharmaceuticals, Inc. (IRWD)
USD 0.65
(-31.48%)
USD 0.65
(-31.48%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 442.73 Million USD | 7.83% |
| 2022 | 410.59 Million USD | -0.76% |
| 2021 | 413.75 Million USD | 6.22% |
| 2020 | 389.52 Million USD | -9.08% |
| 2019 | 428.41 Million USD | 23.59% |
| 2018 | 346.63 Million USD | 16.21% |
| 2017 | 298.27 Million USD | 8.88% |
| 2016 | 273.95 Million USD | 83.18% |
| 2015 | 149.55 Million USD | 95.66% |
| 2014 | 76.43 Million USD | 234.06% |
| 2013 | 22.88 Million USD | -84.77% |
| 2012 | 150.24 Million USD | 128.09% |
| 2011 | 65.87 Million USD | 50.19% |
| 2010 | 43.85 Million USD | 21.48% |
| 2009 | 36.1 Million USD | 62.5% |
| 2008 | 22.21 Million USD | 112.31% |
| 2007 | 10.46 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 74.87 Million USD | -36.3% |
| 2024 Q2 | 94.39 Million USD | 26.07% |
| 2023 Q3 | 113.73 Million USD | 5.92% |
| 2023 Q4 | 117.55 Million USD | 3.35% |
| 2023 Q1 | 104.06 Million USD | -2.93% |
| 2023 Q2 | 107.38 Million USD | 3.19% |
| 2023 FY | 442.73 Million USD | 7.83% |
| 2022 Q2 | 97.23 Million USD | -0.31% |
| 2022 Q3 | 108.63 Million USD | 11.73% |
| 2022 Q4 | 107.19 Million USD | -1.32% |
| 2022 FY | 410.59 Million USD | -0.76% |
| 2022 Q1 | 97.52 Million USD | -16.73% |
| 2021 Q4 | 117.13 Million USD | 12.9% |
| 2021 FY | 413.75 Million USD | 6.22% |
| 2021 Q2 | 104.03 Million USD | 17.09% |
| 2021 Q1 | 88.84 Million USD | -23.86% |
| 2021 Q3 | 103.74 Million USD | -0.27% |
| 2020 FY | 389.52 Million USD | -9.08% |
| 2020 Q3 | 103.46 Million USD | 15.69% |
| 2020 Q2 | 89.43 Million USD | 11.87% |
| 2020 Q1 | 79.94 Million USD | -36.7% |
| 2020 Q4 | 116.68 Million USD | 12.77% |
| 2019 Q1 | 68.73 Million USD | -47.41% |
| 2019 Q3 | 131.16 Million USD | 28.32% |
| 2019 Q4 | 126.3 Million USD | -3.71% |
| 2019 FY | 428.41 Million USD | 23.59% |
| 2019 Q2 | 102.21 Million USD | 48.72% |
| 2018 Q3 | 65.68 Million USD | -19.01% |
| 2018 FY | 346.63 Million USD | 16.21% |
| 2018 Q1 | 69.15 Million USD | -26.59% |
| 2018 Q2 | 81.1 Million USD | 17.28% |
| 2018 Q4 | 130.69 Million USD | 98.96% |
| 2017 Q4 | 94.2 Million USD | 8.5% |
| 2017 Q3 | 86.82 Million USD | 33.42% |
| 2017 FY | 298.27 Million USD | 8.88% |
| 2017 Q2 | 65.07 Million USD | 24.75% |
| 2017 Q1 | 52.16 Million USD | -40.35% |
| 2016 FY | 273.95 Million USD | 83.18% |
| 2016 Q4 | 87.45 Million USD | 32.3% |
| 2016 Q3 | 66.1 Million USD | 21.63% |
| 2016 Q2 | 54.35 Million USD | -17.7% |
| 2016 Q1 | 66.04 Million USD | 23.89% |
| 2015 Q4 | 53.3 Million USD | 34.71% |
| 2015 Q2 | 27.74 Million USD | -4.11% |
| 2015 Q3 | 39.57 Million USD | 42.63% |
| 2015 Q1 | 28.93 Million USD | -24.01% |
| 2015 FY | 149.55 Million USD | 95.66% |
| 2014 Q1 | 14.6 Million USD | 190.3% |
| 2014 Q3 | 16.91 Million USD | 147.34% |
| 2014 Q4 | 38.07 Million USD | 125.04% |
| 2014 FY | 76.43 Million USD | 234.06% |
| 2014 Q2 | 6.84 Million USD | -53.17% |
| 2013 FY | 22.88 Million USD | -84.77% |
| 2013 Q2 | 9.66 Million USD | 196.87% |
| 2013 Q3 | 4.93 Million USD | -48.96% |
| 2013 Q4 | 5.03 Million USD | 2.01% |
| 2013 Q1 | 3.25 Million USD | -87.94% |
| 2012 Q1 | 12.24 Million USD | -61.91% |
| 2012 FY | 150.24 Million USD | 128.09% |
| 2012 Q3 | 96.41 Million USD | 560.18% |
| 2012 Q2 | 14.6 Million USD | 19.24% |
| 2012 Q4 | 26.98 Million USD | -72.02% |
| 2011 Q2 | 11.26 Million USD | 10.01% |
| 2011 Q4 | 32.15 Million USD | 163.17% |
| 2011 FY | 65.87 Million USD | 50.19% |
| 2011 Q3 | 12.21 Million USD | 8.49% |
| 2011 Q1 | 10.23 Million USD | -38.96% |
| 2010 Q4 | 16.77 Million USD | 85.14% |
| 2010 FY | 43.85 Million USD | 21.48% |
| 2010 Q2 | 10.95 Million USD | 21.07% |
| 2010 Q1 | 9.05 Million USD | 5.21% |
| 2010 Q3 | 9.05 Million USD | -17.34% |
| 2009 FY | 36.1 Million USD | 62.5% |
| 2009 Q1 | 5.23 Million USD | 5.17% |
| 2009 Q2 | 6.61 Million USD | 26.36% |
| 2009 Q3 | 15.25 Million USD | 130.82% |
| 2009 Q4 | 8.6 Million USD | -43.61% |
| 2008 Q4 | 4.97 Million USD | 0.0% |
| 2008 FY | 22.21 Million USD | 112.31% |
| 2007 FY | 10.46 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 21.884% |
| Embecta Corp. | 1.12 Billion USD | 60.498% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 9.055% |
| Dynavax Technologies Corporation | 232.28 Million USD | -90.601% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -280.572% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 34.407% |
| PainReform Ltd. | - USD | -Infinity% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -775.264% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -1737.625% |
| SCYNEXIS, Inc. | 140.14 Million USD | -215.921% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -22857.516% |
| Cosmos Health Inc. | 53.37 Million USD | -729.451% |
| Journey Medical Corporation | 79.18 Million USD | -459.143% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -1737.625% |
| Safety Shot Inc | 202.67 Thousand USD | -218351.177% |
| Alpha Teknova, Inc. | 36.68 Million USD | -1106.889% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 4.659% |
| Bright Green Corporation | 401.49 Thousand USD | -110172.708% |
| Procaps Group, S.A. | 409.92 Million USD | -8.005% |
| Theratechnologies Inc. | 81.76 Million USD | -441.479% |
| Harrow Health, Inc. | 130.19 Million USD | -240.061% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -3376.521% |
| Biofrontera Inc. | 34.07 Million USD | -1199.448% |
| DURECT Corporation | 8.54 Million USD | -5079.399% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 27.124% |
| Cronos Group Inc. | 88.84 Million USD | -398.346% |
| OptiNose, Inc. | 70.98 Million USD | -523.685% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -6697.532% |
| Organogenesis Holdings Inc. | 433.14 Million USD | -2.215% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -3514.591% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -1019.36% |
| Radius Health, Inc. | 2.88 Billion USD | 84.639% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -1270.326% |
| ProPhase Labs, Inc. | 44.38 Million USD | -897.51% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 56.496% |
| Procaps Group S.A. | 409.92 Million USD | -8.005% |
| Alvotech | 91.43 Million USD | -384.213% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -33904.224% |
| Viatris Inc. | 15.42 Billion USD | 97.13% |
| Rockwell Medical, Inc. | 83.61 Million USD | -429.511% |
| Aytu BioPharma, Inc. | 81 Million USD | -446.573% |
| SIGA Technologies, Inc. | 139.91 Million USD | -216.426% |
| Tilray Brands, Inc. | 788.94 Million USD | 43.882% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -245.183% |
| Shineco, Inc. | 9.8 Million USD | -4416.849% |
| PetIQ, Inc. | 1.1 Billion USD | 59.823% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -3689358.333% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 76.539% |
| Alimera Sciences, Inc. | 80.75 Million USD | -448.251% |
| Silver Spike Investment Corp. | 11.72 Million USD | -3676.915% |
| Assertio Holdings, Inc. | 152.06 Million USD | -191.141% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -7504.011% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -2441.97% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -41030.894% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -1483.289% |
| Hempacco Co., Inc. | 4.04 Million USD | -10843.518% |
| Talphera, Inc. | 651 Thousand USD | -67908.449% |
| Alvotech | 91.43 Million USD | -384.213% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | -39.836% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 65.85% |
| Currenc Group, Inc. | 53.25 Million USD | -731.344% |
| Kamada Ltd. | 144.75 Million USD | -205.843% |
| Indivior PLC | 1.09 Billion USD | 59.494% |
| Evoke Pharma, Inc. | 5.18 Million USD | -8445.968% |
| Flora Growth Corp. | 76.07 Million USD | -482.002% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -41030.894% |
| Evolus, Inc. | 202.08 Million USD | -119.084% |
| HUTCHMED (China) Limited | 837.99 Million USD | 47.168% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 31.294% |
| Akanda Corp. | 2.16 Million USD | -20396.497% |